Received Oct 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | DN273 | — |
adult female patient got a pediatric dose of Havrix instead of the corresponding adult dose; adult female patient got a pediatric dose of Havrix instead of the corresponding adult dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 31-year-old female patient who received HAV (Havrix pediatric) (batch number DN273, expiry date 28-AUG-2026) for prophylaxis. Previously administered products included Havrix (1st dose received on an unknown date). On 18-SEP-2025, the patient received the 2nd dose of Havrix pediatric. On 18-SEP-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: adult female patient got a pediatric dose of Havrix instead of the corresponding adult dose) and underdose (Verbatim: adult female patient got a pediatric dose of Havrix instead of the corresponding adult dose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-SEP-2025 On 23rd September 2025, a medical assistant called to inform that an adult female patient got a pediatric dose of Havrix instead of the corresponding adult dose which led to adult use of child product and underdose. She called to know how to proceed. She informed it was the second dose of the vaccine series.